The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

The present invention relates to new cathepsin B inhibitors, which are effective in therapy, and in particular in the treatment of diseases associated with an impaired activity of the -galactosidase, such as GM-1 gangliosidosis, Morquio syndrome type B, Chediak-Higashi Syndrome, Galactosialidosis, Metachromatic leukodystrophy, Gaucher Disease, Alzheimer disease and traumatic brain injury.

The present invention relates to new cathepsin B inhibitors, which are effective in therapy, and in particular in the treatment of diseases associated with an impaired activity of the -galactosidase, such as GM-1 gangliosidosis, Morquio syndrome type B, Chediak-Higashi Syndrome, Galactosialidosis, Metachromatic leukodystrophy, Gaucher Disease, Alzheimer disease and traumatic brain injury.

The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.

The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity.

This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: ##STR00001##
wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: ##STR00002##
R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen or lower alkyl, R.sup.4 is lower alkyl, hydroxyl, carboxyl, or amine, R.sup.5 is hydrogen, lower alkyl, or halide, R.sup.6 is hydroxyl or substituted thiol, and each R.sup.7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.

Disclosed herein are biobased epoxy soyates and carboxylates, compositions containing such soyates and carboxylates, methods of preparation and methods of use thereof. Disclosed is an epoxy soyate of Formula (I): (RO).sub.nR.sub.1 (I) wherein n is an integer from 1 to 4 and R and R.sub.1 are chosen from various organic and epoxidized substitutions. Further disclosed is an epoxy carboxylate of Formula (II): (RO).sub.nR.sub.1 (II) wherein n is an integer from 1 to 4, R.sub.1 is chosen from various organic and epoxidized substitutions, and R is an epoxidized dicarboxylic acyl derived from a variety bioderived dicarboxylic acids.

Disclosed herein are biobased epoxy soyates and carboxylates, compositions containing such soyates and carboxylates, methods of preparation and methods of use thereof. Disclosed is an epoxy soyate of Formula (I): (RO).sub.nR.sub.1 (I) wherein n is an integer from 1 to 4 and R and R.sub.1 are chosen from various organic and epoxidized substitutions. Further disclosed is an epoxy carboxylate of Formula (II): (RO).sub.nR.sub.1 (II) wherein n is an integer from 1 to 4, R.sub.1 is chosen from various organic and epoxidized substitutions, and R is an epoxidized dicarboxylic acyl derived from a variety bioderived dicarboxylic acids.